Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60
March 16, 2016 9:46 AM EDTRBC Capital maintained a Sector Perform rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $0.60 (from $1.00), following the company's announced termination of the Takeda partnership. OREX plans to commercialize Contrave in the US by building its own commercial infrastructure. As... More
Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to Neutral
March 16, 2016 6:35 AM EDTPiper Jaffray downgraded Orexigen Therapeutics (NASDAQ: OREX) from Overweight to Neutral with a price target of $2.00 (from $5.00).
Analyst Charles Duncan commented, "Yesterday Orexigen announced it plans to terminate its commercial partnership with Takeda for Contrave in the US market. We believe this... More
JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market Perform
March 16, 2016 6:34 AM EDTJMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform to Market Perform and removed its price target (prior $2.00).
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $0.64 yesterday.
... MoreOrexigen Therapeutics (OREX) Files $150M Mixed Shelf
March 15, 2016 5:26 PM EDTOrexigen Therapeutics (NASDAQ: OREX) filed a registration with the U.S. SEC to sell up to $150 million worth of mixed securities.
... MoreOrexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)
March 15, 2016 7:03 AM EDTOrexigen Therapeutics, Inc. (Nasdaq: OREX) announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro,... More
Orexigen (OREX), Takeda to Terminate CONTRAVE Amended, Restated Collaboration Agreement
March 15, 2016 7:01 AM EDTOrexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, announced they have agreed to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCl / bupropion HCl), the market leading national branded prescription treatment option for certain overweight and obese adults for... More
